Jose J Echegaray1, Thomas Plesec2, Claudine Bellerive1, Arun D Singh1. 1. Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA. 2. Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Abstract
PURPOSE: Histologic correlation of clinical patterns of recurrent choroidal melanoma following I-125 plaque brachytherapy was performed to identify pathologic mechanisms of recurrence. METHODS: We reviewed 7 cases of recurrent choroidal melanoma following I-125 plaque brachytherapy managed with enucleation. Clinical characteristics included tumor dimensions, radiation dose, time to local recurrence, and clinical pattern of recurrence. Histopathology (hematoxylin and eosin and periodic acid - Schiff) and immunohistochemistry (Ki-67, CD-163, HMB45, and SOX10) were performed. RESULTS: Mean follow-up time and time to local recurrence were 42 and 21 months after brachytherapy, respectively. Tumor recurrences were described clinically as marginal in 43%, diffuse in 29%, and extraocular extension (EOE) in 29%. Eighty-six percent were classified as mixed cell type and 14% were epithelioid type. Tumor zonation (histologic demarcation between zones of recurrent and nonrecurrent tumor cells by immunohistochemistry) was present in marginal and EOE cases (n = 6) and absent in the diffuse cases (n = 2). Ki-67 proliferative index was higher in marginal and EOE recurrences, while diffuse cases showed uniform -Ki-67 staining. CD-163 staining was found to be greater in nonrecurrent tumor. HMB45 correlated with SOX10 with a greater staining in recurrent tumor. CONCLUSION: Our observations provide a correlation between histopathologic and clinical patterns of local recurrence of choroidal melanoma after brachytherapy.
PURPOSE: Histologic correlation of clinical patterns of recurrent choroidal melanoma following I-125 plaque brachytherapy was performed to identify pathologic mechanisms of recurrence. METHODS: We reviewed 7 cases of recurrent choroidal melanoma following I-125 plaque brachytherapy managed with enucleation. Clinical characteristics included tumor dimensions, radiation dose, time to local recurrence, and clinical pattern of recurrence. Histopathology (hematoxylin and eosin and periodic acid - Schiff) and immunohistochemistry (Ki-67, CD-163, HMB45, and SOX10) were performed. RESULTS: Mean follow-up time and time to local recurrence were 42 and 21 months after brachytherapy, respectively. Tumor recurrences were described clinically as marginal in 43%, diffuse in 29%, and extraocular extension (EOE) in 29%. Eighty-six percent were classified as mixed cell type and 14% were epithelioid type. Tumor zonation (histologic demarcation between zones of recurrent and nonrecurrent tumor cells by immunohistochemistry) was present in marginal and EOE cases (n = 6) and absent in the diffuse cases (n = 2). Ki-67 proliferative index was higher in marginal and EOE recurrences, while diffuse cases showed uniform -Ki-67 staining. CD-163 staining was found to be greater in nonrecurrent tumor. HMB45 correlated with SOX10 with a greater staining in recurrent tumor. CONCLUSION: Our observations provide a correlation between histopathologic and clinical patterns of local recurrence of choroidal melanoma after brachytherapy.
Authors: Benjamin King; Vanessa M Morales-Tirado; Henry G Wynn; Brad T Gao; Matthew T Ballo; Matthew W Wilson Journal: Am J Ophthalmol Date: 2016-12-31 Impact factor: 5.258
Authors: J Pe'er; F H Stefani; S Seregard; T Kivela; P Lommatzsch; J U Prause; B Sobottka; B Damato; I Chowers Journal: Br J Ophthalmol Date: 2001-10 Impact factor: 4.638
Authors: Gerard J M J van den Aardweg; Nicole C Naus; Anette C A Verhoeven; Annelies de Klein; Gregorius P M Luyten Journal: Invest Ophthalmol Vis Sci Date: 2002-08 Impact factor: 4.799
Authors: Robert B Avery; Marie Diener-West; Sandra M Reynolds; Hans E Grossniklaus; W Richard Green; Daniel M Albert Journal: Arch Ophthalmol Date: 2008-02